MARIANNE (NCT01120184): The MARIANNE trial enrolled 1,095 patients with HER2-positive advanced breast cancer and randomized them to receive T-DM1 plus pertuzumab, T-DM1 plus placebo, or trastuzumab plus a taxane. Here, ERBB2 is linked to breast carcinoma.